切换至 "中华医学电子期刊资源库"

中华危重症医学杂志(电子版) ›› 2018, Vol. 11 ›› Issue (04) : 244 -249. doi: 10.3877/cma.j.issn.1674-6880.2018.04.006

所属专题: 文献

论著

无创正压通气联合雾化吸入对慢性阻塞性肺疾病加重期患者的疗效分析
许群锋1,(), 倪慧萍2   
  1. 1. 213003 江苏常州,常州市中医医院急诊内科
    2. 213000 江苏常州,常州市第一人民医院呼吸科
  • 收稿日期:2018-03-12 出版日期:2018-08-01
  • 通信作者: 许群锋
  • 基金资助:
    常州市科技计划(应用基础研究)指导性项目(2014272)

Effect of noninvasive positive pressure ventilation combined with nebulization on patients with exacerbation of chronic obstructive pulmonary disease

Qunfeng Xu1,(), Huiping Ni2   

  1. 1. Department of Emergency Medicine, Changzhou Traditional Chinese Medicine Hospital, Changzhou 213003, China
    2. Department of Respiratory, the First People's Hospital of Changzhou, Changzhou 213000, China
  • Received:2018-03-12 Published:2018-08-01
  • Corresponding author: Qunfeng Xu
  • About author:
    Corresponding author: Xu Qunfeng, Email:
引用本文:

许群锋, 倪慧萍. 无创正压通气联合雾化吸入对慢性阻塞性肺疾病加重期患者的疗效分析[J/OL]. 中华危重症医学杂志(电子版), 2018, 11(04): 244-249.

Qunfeng Xu, Huiping Ni. Effect of noninvasive positive pressure ventilation combined with nebulization on patients with exacerbation of chronic obstructive pulmonary disease[J/OL]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2018, 11(04): 244-249.

目的

分析慢性阻塞性肺疾病加重期(AECOPD)患者行无创正压通气联合布地奈德、异丙托溴铵雾化吸入治疗的临床疗效及患者血清中肺部活化调节趋化因子配体18(CCL-18)和生长分化因子15(GDF-15)表达水平变化情况。

方法

将在常州市中医医院门诊就诊的80例AECOPD患者采用随机信封法分为观察组及对照组,每组各40例。对照组采用正压通气治疗,观察组采用无创正压通气联合布地奈德、异丙托溴铵雾化吸入治疗。对两组患者的临床疗效、治疗前及治疗结束后72 h的呼吸困难评分、肺功能、动脉血气分析以及血清中的CCL18和GDF-15水平进行评估,记录两组患者不良反应发生情况。

结果

观察组患者的临床有效率较对照组显著提高[80.00%(32/40)vs. 67.50%(27/40),χ2= 4.036,P= 0.045]。两组患者治疗后的第一秒用力呼气容积(FEV1)[(1.69 ± 0.23)L vs.(1.43 ± 0.19)L]、FEV1占用力肺活量(FVC)百分比[(71 ± 4)% vs.(65 ± 4)%]、最大呼气流速(PEF)[(3.98 ± 0.27)L/s vs.(3.15 ± 0.31)L/s]、呼吸困难评分[(1.02 ± 0.27)分vs.(1.65 ± 0.32)分]、肺泡氧分压(PaO2)[(87.4 ± 1.8)mmHg vs.(70.2 ± 2.0)mmHg]、动脉血二氧化碳分压(PaCO2)[(41 ± 5)mmHg vs.(59 ± 3)mmHg]、pH值[(7.43 ± 0.03)vs.(7.33 ± 0.02)]、动脉血氧饱和度(SaO2)[(95.7 ± 2.1)% vs.(91.2 ± 2.1)%]、CCL-18[(1.13 ± 0.12)μg/L vs.(1.68 ± 0.21)μg/L]及GDF-15[(0.61 ± 0.12)μg/L vs.(1.02 ± 0.22)μg/L]水平比较,差异均有统计学意义(t= 3.968、8.011、9.387、6.870、47.220、19.562、13.519、12.385、10.386、10.347,P均< 0.05);观察组患者治疗前后FEV1、FEV1/FVC、PEF、呼吸困难评分、PaO2、PCO2、pH、SaO2、CCL-18及GDF-15水平比较,差异均有统计学意义(t= 6.311、21.727、12.276、20.406、68.100、27.028、14.952、24.845、21.361、35.294,P均< 0.05)。两组患者不良反应发生率比较,差异无统计学意义[12.50%(5/40)vs. 17.50%(7/40),χ2= 0.980,P= 0.322]。

结论

采用无创正压通气联合布地奈德、异丙托溴铵雾化吸入治疗AECOPD患者可显著提高临床疗效,并改善血清中CCL-18及GDF-15水平。

Objective

To analyze the clinical effect of noninvasive positive pressureventilation combined with budesonide and ipratropium nebulization and the changes of serum CC-chemokine ligand 18 (CCL-18) and growth differentiation factor 15 (GDF-15) in patients with chronic obstructive pulmonary disease (AECOPD).

Methods

Eighty AECOPD patients in Changzhou Traditional Chinese Medicine Hospital were randomly divided into the observation group (n= 40) and control group (n= 40). The control group was treated with positive pressure ventilation, and the observation group was treated with noninvasive positive pressure ventilation combined with budesonide and ipratropium nebulization. The clinical efficacy, dyspnea score, pulmonary function, arterial blood gas and serum CCL-18 and GDF-15 levels before and 72 hours after treatment in both groups were evaluated. Meanwhile, the occurrence of adverse reactions in patients was recorded.

Results

The clinical effective rate of the observation group was significantly higher than that of the control group [80.00% (32/40) vs. 67.50% (27/40), χ2= 4.036, P= 0.045]. The expressions of forced expiratory volume in one second (FEV1) [(1.69 ± 0.23) L vs. (1.43 ± 0.19) L], ratio of FEV1/forced vital capacity (FEV1/FVC) [(71 ± 4)% vs. (65 ± 4)%], peak expiratory flow (PEF) [(3.98 ± 0.27) L/s vs. (3.15 ± 0.31) L/s], dyspnea score [(1.02 ± 0.27) vs. (1.65 ± 0.32)], alveolar oxygen partial pressure (PaO2) [(87.4 ± 1.8) mmHg vs. (70.2 ± 2.0) mmHg], partial pressure of carbon dioxide in artery (PCO2) [(41 ± 5) mmHg vs. (59 ± 3) mmHg], pH [(7.43 ± 0.03) vs. (7.33 ± 0.02)], arterial oxygen saturation (SaO2) [(95.7 ± 2.1)% vs. (91.2 ± 2.1)%], CCL-18 [(1.13 ± 0.12) μg/L vs. (1.68 ± 0.21) μg/L] and GDF-15 [(0.61 ± 0.12) μg/L vs. (1.02 ± 0.22) μg/L] after treatment of these two groups were statistically significantly different (t= 3.968, 8.011, 9.387, 6.870, 47.220, 19.562, 13.519, 12.385, 10.386, 10.347; all P < 0.05). The FEV1, FEV1/FVC, PEF, dyspnea score, PaO2, PCO2, pH, SaO2, CCL-18 and GDF-15 levels before and after treatment in the observation group were significantly different (t= 6.3111, 21.727, 12.276, 20.406, 68.100, 27.028, 14.952, 24.845, 21.361, 35.294; all P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups [12.50% (5/40) vs. 17.50% (7/40); χ2= 0.980, P= 0.322].

Conclusion

Noninvasive positive pressure ventilation combined with budesonide and ipratropium nebulization can significantly improve the clinical efficacy and levels of serum CCL-18 and GDF-15 in AECOPD patients.

表1 两组AECOPD患者一般资料比较
表2 两组AECOPD患者FEV1、FEV1/FVC及PEF水平的比较(±s
表3 两组AECOPD患者动脉血气分析(±s
1
Turner AM,Lim WS,Rodrigo C, et al. A care-bun-dles approach to improving standard of care in AECOPD admissions: results of a national project[J]. Thorax, 2015, 70(10): 992-994.
2
Wang W,Ying Y,Wu Q, et al. A GIS-based spatial correlation analysis for ambient air pollution and AECOPD hospitalizations in Jinan, China[J]. Respir Med, 2015, 109(3): 372-378.
3
石齐芳,梁大胜. AECOPD合并呼吸衰竭患者有创-无创序贯撤机时再插管的相关因素分析[J]. 医学综述, 2015, 22(15):2845-2847.
4
Munoz-Esquerre M,Aliagas E,López-Sánchez M, et al. Vascular disease in COPD: systemic and pulmonary expression of PARC (pulmonary and qctivation-regulated chemokine)[J]. PLoS One, 2017, 12(5): e0177218.
5
Moretti M,Fagnani S. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD[J]. Int J Chron Obstruct Pulmon Dis, 2015 (10): 2319-2325.
6
Zhao X,Wang H,Song D, et al. Study on effect of Combivent combined with glucocorticoids in the treatment of patients with AECOPD[J]. Pak J Pharm Sci, 2016, 29(6 Spec): 2199-2205.
7
刘欣欣,王浩彦,张曼林, 等. 改良版英国医学研究会呼吸困难量表评分及肺功能测定对慢性阻塞性肺疾病患者运动能力的预测价值研究[J]. 临床内科杂志, 2016, 33(6):404-406.
8
Hillas G,Perlikos F,Tzanakis N. Acute exacerbation of COPD: is it the "stroke of the lungs" ?[J]. Int J Chron Obstruct Pulmon Dis, 2016 (11): 1579-1586.
9
Santharam S,Lugg ST,Packer G, et al. P210 imple-mentation of electronic copd discharge care bundles: a quality improvement project[J]. Thorax, 2016, 71(Suppl 3): A198-A199.
10
栗娜,刘旭升,赵民建. 不同压力支持水平无创正压通气治疗慢性阻塞性肺疾病急性加重期的临床效果研究[J]. 实用心脑肺血管病杂志, 2015, 26(3):22-24.
11
Lin YH,Tsai CL,Chien LN, et al. Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis-a nationwide population-based cohort study[J]. Int J Clin Pract, 2015, 69(3): 350-357.
12
Sanchez-Morillo D,Fernandez-Granero MA,Jiménez AL. Detecting COPD exacerbations early using daily telemonitoring of symptoms and k-means clustering: a pilot study[J]. Med Biol Eng Comput, 2015, 53(5): 441-451.
13
邓小春,孔梅. 大剂量氨溴索应用于气管气道分泌物增多的临床疗效及安全性分析[J]. 临床肺科杂志, 2016, 21(7):1210-1212.
14
黄颖,文智能. 异丙托溴铵雾化吸入联合舒血宁注射液对AECOPD患者肺功能及血清MMP-9、MCP-1水平变化的影响[J]. 中国地方病防治杂志, 2018, 33(2):235-237.
15
Fruchter O,Yigla M,Kramer MR. Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease[J]. Am J Med Sci, 2015, 349(4): 338-343.
16
段艳红,周红. 血清SP-D、CC16在AECOPD患者中的表达及其意义[J]. 医学临床研究, 2015, 32(8):1556-1558.
17
汤军华,赵德军,张晓燕, 等. 布地奈德/福莫特罗与噻托溴铵吸入治疗对不同表型重度稳定期慢性阻塞性肺疾病患者的临床对比研究[J/CD]. 中华危重症医学杂志(电子版), 2016, 9(4):268-270.
18
崔婧,贾方,孙建辉. 生长分化因子-15与心血管疾病[J]. 国际心血管病杂志, 2018, 45(1):35-38.
19
Takir HB,Esquinas AM. Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units[J]. Int J Chron Obstruct Pulmon Dis, 2017 (12): 783-784.
20
于海侠,周景霞,任长安, 等. 心肺复苏患者血清GDF-15、NT-proBNP、cTnI水平变化的临床意义及其与近期预后的关系[J]. 中国动脉硬化杂志, 2017, 25(3):269-273.
[1] 岳伟岗, 蒋由飞, 尹瑞元, 吴雨晨, 曾丽, 田金徽. 经鼻高流量氧疗对急性低氧性呼吸衰竭患者住院病死率的累积Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(01): 39-44.
[2] 黄来明, 张旭东. 雾化吸入布地奈德混悬液联合气管导管涂抹达克罗宁胶浆对改善妇科腹腔镜手术气管插管全身麻醉患者咽喉部不适作用[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 480-486.
[3] 袁广琴, 朱珠, 林云霞. 胸腺肽联合无创正压通气救治AECOPD并发Ⅱ型呼吸衰竭患者的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 438-441.
[4] 陈婷婷, 李春娟. 经鼻高流量湿化氧疗治疗AECOPD伴Ⅱ型呼吸衰竭的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 276-279.
[5] 周玲, 吴园明. 复方异丙托溴铵对AECOPD患者肺功能及血清IGF-Ⅱ、SOD水平的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(01): 103-106.
[6] 杨明福, 王永兴. HFNC与NPPV在AECOPD伴Ⅱ型呼吸衰竭中的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(06): 804-808.
[7] 刘玉强, 吴秀秀, 李晓辉, 王瑜, 韩国霖, 张伟, 王俊芝, 侯春霞. 瑞舒伐他汀钙联合激素气道雾化对AECOPD并发肺动脉高压的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(05): 670-672.
[8] 顾玲, 赵颖, 伯雪, 王霞, 张扬, 李琼, 杨永静, 褚玲玲. 布地奈德联合干扰素雾化吸入治疗对病毒性肺炎的临床疗效[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(05): 727-728.
[9] 郭长江, 冷建刚, 邵伟. 阿莫西林克拉维酸钾联合布地奈德治疗小儿反复细菌性呼吸道感染[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(03): 394-396.
[10] 丁晓静, 张丹琦, 杨伟. 布地奈德雾化吸入联合金嗓开音胶囊治疗小儿急性喉炎的疗效及对IFN-γ、SAA、IL-6的影响[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(03): 391-393.
[11] 张松涛, 李世金, 凌霄, 吴文辉. 胸部物理治疗联合布地奈德雾化对多发伤患者并发ARDS的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(03): 373-375.
[12] 宣瑞萍, 刘笑琴, 王平, 查日田. 无创正压通气与经鼻高流量氧疗治疗AECOPD合并Ⅱ型呼吸衰竭的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(03): 346-348.
[13] 陈先志, 许磊, 冯其柱, 王琦. 布地奈德联合复方异丙托溴铵雾化吸入在老年患者腹腔镜围手术期中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 531-536.
[14] 苑乐添, 王艺霖, 沈子剑, 闫呈新. 血清GDF15、sB7-H1联合多层螺旋CT灌注成像技术对胃癌患者淋巴结转移的诊断价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 62-66.
[15] 何秀, 敖的, 杨郑, 林小华. 改良呼吸支持策略对慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭患者的疗效[J/OL]. 中华卫生应急电子杂志, 2024, 10(03): 140-144.
阅读次数
全文


摘要